Table 2.
Vaccine Response at Each Postvaccination Timepoint
| 95% CI | |||||||
|---|---|---|---|---|---|---|---|
| Group | Postvaccination Timepoint | N | n | % | LL | UL | |
| ChAd155-RSV-LD | D30 | 5 | 1 | 20.0 | .5 | 71.6 | |
| D60 | 5 | 1 | 20.0 | .5 | 71.6 | ||
| ChAd155-RSV-HD | D30 | 26 | 15 | 57.7 | 36.9 | 76.6 | |
| D60 | 26 | 15 | 57.7 | 36.9 | 76.6 | ||
| Placebo | D30 | 18 | 3 | 16.7 | 3.6 | 41.4 | |
| D60 | 18 | 1 | 5.6 | .1 | 27.3 | ||
| Active | D30 | 15 | 1 | 6.7 | .2 | 31.9 | |
| D60 | 15 | 2 | 13.3 | 1.7 | 40.5 | ||
Vaccine response was defined as: at least a 4-fold increase in prevaccination titre <7 log2; at least a 3-fold increase in prevaccination titre in [7, 8] log2; at least a 2.5-fold increase in prevaccination titre in [8–10] log2; at least a 1-fold increase in prevaccination titre >10 log2. The placebo was a saline solution and the active dose was Bexsero.Abbreviations: ChAd155, chimpanzee-adenovirus-155 vaccine; CI, confidence interval; D, day; HD, high dose; LD, low dose; LL, lower limit; N, number of participants with both pre- and postvaccination results available; n, number of participants meeting the vaccine response definition within each group; RSV, respiratory syncytial virus; UL, upper limit.